Loading company information...
公司資料
新聞
TrustFinance 情報機構
研究日期: Thg 10 14, 2025
Sigma Healthcare plans to merge with Chemist Warehouse, creating a company with a market cap near $9 billion. Major broker Macquarie has raised concerns regarding the merger's potential risks, particularly that the ACCC may block it due to market power concerns. Macquarie estimates a 60% chance of successful completion, suggesting a fair value of $0.88 per Sigma share, down from its previous rating of 'Neutral' to 'Underperform'.
Sigma Healthcare plans to merge with Chemist Warehouse, creating a company with a market cap near $9 billion. Major broker Macquarie has raised concerns regarding the merger's potential risks, particularly that the ACCC may block it due to market power concerns. Macquarie estimates a 60% chance of successful completion, suggesting a fair value of $0.88 per Sigma share, down from its previous rating of 'Neutral' to 'Underperform'.
Chemist Warehouse is planning to list on the ASX through a reverse takeover by Sigma Healthcare. The deal, valued at $700 million in cash and shares, will result in CWG shareholders owning 85.75% of the merged entity, which is expected to become a major player in the Australian pharmaceuticals market. The merger aims to create substantial synergies, with projected EBIT of around $495 million and a market cap of $8.8 billion, potentially adding the company to major ASX indices. The merger is subject to regulatory approval and has raised concerns from industry groups regarding its impact on community pharmacies.
Chemist Warehouse is planning to list on the ASX through a reverse takeover by Sigma Healthcare. The deal, valued at $700 million in cash and shares, will result in CWG shareholders owning 85.75% of the merged entity, which is expected to become a major player in the Australian pharmaceuticals market. The merger aims to create substantial synergies, with projected EBIT of around $495 million and a market cap of $8.8 billion, potentially adding the company to major ASX indices. The merger is subject to regulatory approval and has raised concerns from industry groups regarding its impact on community pharmacies.
由TrustFinance AI分析提供
